Who
Rachel E. Haurwitz
President and CEO
Company insider
Files Form 4 as: President and CEO, Caribou Biosciences; Director, Seer; Director and 10% owner, Intellia Therapeutics.
In numbers
- Trades disclosed
- 34
- Buys
- 1
- Sells
- 0
- Bought
- $20K
- Sold
- $0
- Companies
- 3
- Companies where not an officer
- 2
- First trade
- 5 May 2016
- Last trade
- 20 Feb 2026
- Last filed
- 20 Feb 2026
Companies traded
Activity over time
1 Mar 2025 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 20 Feb 2026filed 20 Feb 2026 | CRBU Caribou BiosciencesBiotechnology | SEC FORM 4 Code A | —151,700 at $0.00 | filing |
| 20 Feb 2026filed 20 Feb 2026 | CRBU Caribou Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —682,500 at $0.00 | filing |
| 20 Feb 2026filed 20 Feb 2026 | CRBU Caribou Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —682,500 at $0.00 | filing |
| 20 Feb 2026filed 20 Feb 2026 | CRBU Caribou BiosciencesBiotechnology | SEC FORM 4 Code A | —151,700 at $0.00 | filing |
| 14 Mar 2025filed 17 Mar 2025 | CRBU Caribou BiosciencesBiotechnology | SEC FORM 4 Bought | $20K20,000 at $1.02 | filing |
| 20 Feb 2025filed 21 Feb 2025 | CRBU Caribou Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —618,250 at $0.00 | filing |
| 20 Feb 2025filed 21 Feb 2025 | CRBU Caribou BiosciencesBiotechnology | SEC FORM 4 Code A | —136,750 at $0.00 | filing |
| 12 Jun 2024filed 14 Jun 2024 | SEER SeerLife-science tools | SEC FORM 4 Code A | —58,178 at $0.00 | filing |
| 20 Feb 2024filed 22 Feb 2024 | CRBU Caribou Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —546,950 at $0.00 | filing |
| 20 Feb 2024filed 22 Feb 2024 | CRBU Caribou BiosciencesBiotechnology | SEC FORM 4 Code A | —118,700 at $0.00 | filing |
| 14 Jun 2023filed 16 Jun 2023 | SEER Seeroption or derivative · Life-science tools | SEC FORM 4 Code A | —34,735 at $0.00 | filing |
| 14 Jun 2023filed 16 Jun 2023 | SEER SeerLife-science tools | SEC FORM 4 Code A | —23,443 at $0.00 | filing |
| 8 Jun 2023filed 9 Jun 2023 | CRBU Caribou Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code M | —10,000 at $0.00 | filing |
| 8 Jun 2023filed 9 Jun 2023 | CRBU Caribou BiosciencesBiotechnology | SEC FORM 4 Code M | $30K10,000 at $2.96 | filing |
| 20 Mar 2023filed 22 Mar 2023 | CRBU Caribou Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code M | —10,000 at $0.00 | filing |
| 20 Mar 2023filed 22 Mar 2023 | CRBU Caribou BiosciencesBiotechnology | SEC FORM 4 Code M | $30K10,000 at $2.96 | filing |
| 21 Feb 2023filed 23 Feb 2023 | CRBU Caribou Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —510,500 at $0.00 | filing |
| 15 Jun 2022filed 17 Jun 2022 | SEER Seeroption or derivative · Life-science tools | SEC FORM 4 Code A | —17,865 at $0.00 | filing |
| 15 Jun 2022filed 17 Jun 2022 | SEER SeerLife-science tools | SEC FORM 4 Code A | —5,994 at $0.00 | filing |
| 9 May 2022filed 10 May 2022 | CRBU Caribou Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code M | —10,000 at $0.00 | filing |
News
Caribou Biosciences, Inc. (NASDAQ:CRBU) Stock Has Average Price Target of $5.50CRBU · dailypolitical.com · 19 Oct 2026Head to Head Analysis: Caribou Biosciences (NASDAQ:CRBU) & Vertex Pharmaceuticals (NASDAQ:VRTX)CRBU · tickerreport.com · 14 Oct 2026Caribou Biosciences Halts Off-the-Shelf CRISPR CAR-T Programs for Lymphoma and Myeloma After Failing to Fund Phase 3 TrialCRBU · medicaldaily.com · 10 Oct 2026
0 headlines in the last 90 days name Rachel E. Haurwitz; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.